The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19...

Area of Science:

• Immunology
• Neurology
• Virology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Teriflunomide is an immunomodulatory drug commonly used to treat relapsing forms of MS.
• The COVID-19 pandemic raised concerns about the safety of continuing immunomodulatory therapies in patients with active infections.

Purpose of the Study:

• To evaluate the impact of teriflunomide on T-cell immune profiles in a multiple sclerosis patient with concurrent COVID-19 pneumonia.
• To determine if teriflunomide treatment should be discontinued in MS patients experiencing active COVID-19 pneumonia.

Main Methods:

• Case study of a single multiple sclerosis patient treated with teriflunomide.
• Immunophenotyping analysis of peripheral blood cells at two time points: pre-infection and during COVID-19 pneumonia.
• Analysis focused on immune activation and immunosenescence markers in CD4+ and CD8+ T-cells.

Main Results:

• The patient recovered from COVID-19 pneumonia within 15 days.
• No significant differences were observed in the percentages of immune-activated or immune-senescent CD4+ and CD8+ T-cells between the pre-infection and infection time points.
• These findings suggest teriflunomide effectively controls T-cell immune activation and aging.

Conclusions:

• Teriflunomide appears to maintain T-cell homeostasis, even during an active COVID-19 infection.
• Discontinuation of teriflunomide may not be necessary for multiple sclerosis patients with active COVID-19 pneumonia.
• This case study supports the continued use of teriflunomide in MS patients with COVID-19.